Benzodiazepines, Urine Screen with Reflex to Quantitation

2012225

Ordering Recommendation

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out benzodiazepine exposure. For follow-up testing of a presumptive result, Benzodiazepines, Urine Quantitative (2008291) is preferred.

Mnemonic

BENZ RFX U

Methodology

Qualitative Enzyme Immunoassay/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-4 days

New York DOH Approval Status

This test is New York DOH approved.

Submit With Order

ARUP Consult®

Disease Topics

Interface Map

Specimen Required

Patient Preparation
Collect: Random urine.
Specimen Preparation: Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2 mL)
Storage/Transport Temperature: Room Temperature
Unacceptable Conditions: Breast Milk. Pharmaceutical preparation. Specimens exposed to repeated freeze/thaw cycles.
Remarks
Stability: Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years

Reference Interval

Screen cutoff concentration: 200 ng/mL

Interpretive Data

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note

If the specimen screens positive, then Confirmation/Quantitation by LC-MS/MS (ARUP test code 2008291) will be added to confirm result. Additional charges apply.

CPT Code(s)

80307; if positive add 80346 (Alt code: if positive add G0480)

Are you an ARUP Client?
Click here for your pricing.

Components

Component Test Code*	Component Chart Name	LOINC
0092197	Benzodiazepines, Urn, Screen	19284-9
2012212	Screen, Urine Interpretation	54247-2

* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

Pain Management, Benzodiazepines, Quantitative, w/ medMATCH, Urine (Drugs of Abuse Confirmation/Quan
Pain Management, Benzodiazepines, w/Confirmation w/med MATACH, Urine (Drugs of Abuse Confirmation/Qu